{
  "zip": "201203",
  "sector": "Healthcare",
  "fullTimeEmployees": 325,
  "longBusinessSummary": "CStone Pharmaceuticals, a clinical-stage biotechnology company, focuses on developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment worldwide. The company's late-stage clinical products include CS1001, a monoclonal antibody against programmed death ligand 1; CS1003, a monoclonal antibody against programmed death receptor; ivosidenib, a potent inhibitor of the mutated isocitrate dehydrogenase-1 enzyme for the treatment of cancer; avapritinib, an inhibitor for the treatment of gastrointestinal stromal tumors and systematic mastocytosis; and Pralsetinib for the treatment of medullary thyroid cancer and other advanced solid tumors. Its products also comprise CS1002, CS3002, CS3003, CS3005, and CS3006 for solid tumors; Fisogatinib that is used for the treatment of hepatocellular carcinoma; and CS3004, CS1009, and CS2004 for other indications. CStone Pharmaceuticals has a licensing agreement with Numab Therapeutics AG for the development and commercialization of NM21-1480, a potential monovalent tri-specific antibody-based molecule targeting PD-L1, 4-1BB, and human serum albumin; a clinical collaboration with Bayer HealthCare LLC to evaluate CS1001 in combination with Bayer's oral multi-kinase inhibitor Stivarga, as a treatment for various types of cancer, including gastric cancer; and a strategic partnership with Burning Rock Biotech Limited to co-develop and commercialize companion diagnostics for pralsetinib, an investigational treatment for the detection of RET alterations in cancer patients. The company was founded in 2015 in Cayman Islands, and is headquartered in Shanghai, China.",
  "city": "Shanghai",
  "phone": "86 21 6109 7678",
  "country": "China",
  "companyOfficers": [],
  "website": "http://www.cstonepharma.com",
  "maxAge": 1,
  "address1": "Buillding 25",
  "fax": "86 21 6109 7689",
  "industry": "Biotechnology",
  "address2": "1000 Zhangheng Road Pudong New District",
  "previousClose": 1.23,
  "regularMarketOpen": 1.54,
  "twoHundredDayAverage": 1.335,
  "trailingAnnualDividendYield": null,
  "payoutRatio": 0,
  "volume24Hr": null,
  "regularMarketDayHigh": 1.23,
  "navPrice": null,
  "averageDailyVolume10Day": 7412,
  "totalAssets": null,
  "regularMarketPreviousClose": 1.23,
  "fiftyDayAverage": 1.335,
  "trailingAnnualDividendRate": null,
  "open": 1.54,
  "averageVolume10days": 7412,
  "expireDate": null,
  "yield": null,
  "algorithm": null,
  "dividendRate": null,
  "exDividendDate": null,
  "beta": null,
  "circulatingSupply": null,
  "startDate": null,
  "regularMarketDayLow": 1.23,
  "priceHint": 4,
  "currency": "USD",
  "regularMarketVolume": 18290,
  "lastMarket": null,
  "maxSupply": null,
  "openInterest": null,
  "marketCap": 1463527808,
  "volumeAllCurrencies": null,
  "strikePrice": null,
  "averageVolume": 7412,
  "priceToSalesTrailing12Months": null,
  "dayLow": 1.23,
  "ask": null,
  "ytdReturn": null,
  "askSize": null,
  "volume": 18290,
  "fiftyTwoWeekHigh": 2.59,
  "forwardPE": null,
  "fromCurrency": null,
  "fiveYearAvgDividendYield": null,
  "fiftyTwoWeekLow": 1,
  "bid": null,
  "tradeable": false,
  "dividendYield": null,
  "bidSize": null,
  "dayHigh": 1.23,
  "exchange": "PNK",
  "shortName": "CSTONE PHARMACEUTICALS",
  "longName": "CStone Pharmaceuticals",
  "exchangeTimezoneName": "America/New_York",
  "exchangeTimezoneShortName": "EST",
  "isEsgPopulated": false,
  "gmtOffSetMilliseconds": "-18000000",
  "underlyingSymbol": null,
  "quoteType": "EQUITY",
  "symbol": "CSPHF",
  "underlyingExchangeSymbol": null,
  "headSymbol": null,
  "messageBoardId": "finmb_602087748",
  "uuid": "0048c0a6-02e9-3414-b216-aa9478c58d47",
  "market": "us_market",
  "annualHoldingsTurnover": null,
  "enterpriseToRevenue": null,
  "beta3Year": null,
  "profitMargins": 0,
  "enterpriseToEbitda": null,
  "52WeekChange": null,
  "morningStarRiskRating": null,
  "forwardEps": null,
  "revenueQuarterlyGrowth": null,
  "sharesOutstanding": 1171209984,
  "fundInceptionDate": null,
  "annualReportExpenseRatio": null,
  "bookValue": null,
  "sharesShort": null,
  "sharesPercentSharesOut": null,
  "fundFamily": null,
  "lastFiscalYearEnd": 1577750400,
  "heldPercentInstitutions": 0.17353001,
  "netIncomeToCommon": null,
  "trailingEps": null,
  "lastDividendValue": null,
  "SandP52WeekChange": null,
  "priceToBook": null,
  "heldPercentInsiders": 0.26092,
  "nextFiscalYearEnd": 1640908800,
  "mostRecentQuarter": 1593475200,
  "shortRatio": null,
  "sharesShortPreviousMonthDate": null,
  "floatShares": 389239576,
  "enterpriseValue": 1236127872,
  "threeYearAverageReturn": null,
  "lastSplitDate": null,
  "lastSplitFactor": null,
  "legalType": null,
  "morningStarOverallRating": null,
  "earningsQuarterlyGrowth": null,
  "dateShortInterest": null,
  "pegRatio": null,
  "lastCapGain": null,
  "shortPercentOfFloat": null,
  "sharesShortPriorMonth": null,
  "category": null,
  "fiveYearAverageReturn": null,
  "regularMarketPrice": 1.54,
  "logo_url": "https://logo.clearbit.com/cstonepharma.com"
}